Mydecine Innovations Group Inc. (OTCMKTS:MYCOF – Get Free Report)’s share price dropped 8.8% during trading on Tuesday . The company traded as low as $0.73 and last traded at $0.73. 10,000 shares traded hands during mid-day trading, an increase of 174% from the average daily volume of 3,650 shares. The stock had previously closed at $0.80.
Mydecine Innovations Group Trading Down 8.8%
The stock has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $0.97.
About Mydecine Innovations Group
Mydecine Innovations Group (OTCMKTS:MYCOF) is a clinical‐stage biotechnology company dedicated to the research, development and commercialization of novel therapeutics derived from psychedelic and plant-based compounds. The company’s primary focus lies in advancing a pipeline of next‐generation product candidates targeting mental health disorders, addiction and other neurological conditions. Mydecine holds a portfolio of intellectual property that encompasses proprietary chemical entities, drug delivery systems and manufacturing processes for molecules such as 5-MeO-DMT analogs, ibogaine-derived compounds and psilocybin formulations.
Headquartered in Denver, Colorado, with additional research and manufacturing facilities in Vancouver, Canada, Mydecine operates a vertically integrated business model.
Featured Articles
- Five stocks we like better than Mydecine Innovations Group
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Mydecine Innovations Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mydecine Innovations Group and related companies with MarketBeat.com's FREE daily email newsletter.
